Intellia Therapeutics
A Regional Scientific Director at Intellia develops trusted partnerships within the healthcare community for CRISPR-based gene editing programs. The role involves scientific engagement with KOLs, clinical trial support, and providing education on gene editing therapies.
Headquarters
Cambridge, Massachusetts, United States
Company Size
501-1000 employees
Founded
2014
Intellia Therapeutics, a leading clinical-stage genome editing company, is developing novel, potentially curative therapeutics leveraging CRISPR-based technologies.
Intellia Therapeutics Announces FDA Lift of Clinical Hold on MAGNITUDE Phase 3 Clinical Trial in ATTR-CM
1 week ago
Intellia Therapeutics: Why The Clinical Hold Lift Isn't A Total Victory (NASDAQ:NTLA)
3 days ago
Intellia Therapeutics, Inc. (NTLA): A Bull Case Theory
2 weeks ago
Headquarters
San Francisco, CA
Company Size
201-500 employees
Founded
2018
Industry
Technology
Glassdoor Rating
4.2 / 5
Sarah Johnson
Chief Executive Officer
Michael Chen
Chief Technology Officer
Emily Williams
VP of Engineering
David Rodriguez
VP of Product
Jessica Thompson
Chief Financial Officer
Andrew Park
VP of Sales
View leadership team, funding history,
and employee contacts for Intellia Therapeutics.
74% above the average for this role
Intellia Therapeutics Announces Fourth Quarter and Full-Year 2025 Financial Results and Business Updates
2 weeks ago
Scientist II
CRISPR Therapeutics
Post Doctoral Scholar
The Ohio State University
Regional Scientific Director, Southeast
Amylyx Pharmaceuticals
Scientist II, Computational Biology & AI
CRISPR Therapeutics
Postdoctoral Research Associate
Washington University in St. Louis
Research Scientist, Gene Editing Core
Mass General Brigham